{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:24:57Z","timestamp":1791959097363,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T00:00:00Z","timestamp":1443484800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1038\/nrneurol.2015.177","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T09:24:06Z","timestamp":1443518646000},"page":"56-61","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["CAP\u2014advancing the evaluation of preclinical Alzheimer disease treatments"],"prefix":"10.1038","volume":"12","author":[{"given":"Eric M.","family":"Reiman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica B.","family":"Langbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre N.","family":"Tariot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Lopera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall J.","family":"Bateman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reisa A.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Aisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen D.","family":"Roses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen A.","family":"Welsh-Bohmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacie","family":"Weninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,29]]},"reference":[{"key":"BFnrneurol2015177_CR1","doi-asserted-by":"crossref","unstructured":"Alzheimer's Association. 2013 Alzheimer's Disease Facts and Figures. Alzheimers Dement. 9, 208\u2013245 (2013).","DOI":"10.1016\/j.jalz.2013.02.003"},{"key":"BFnrneurol2015177_CR2","doi-asserted-by":"publisher","first-page":"111cm33","DOI":"10.1126\/scitranslmed.3002609","volume":"3","author":"RA Sperling","year":"2011","unstructured":"Sperling, R. A., Jack, C. R. Jr & Aisen, P. S. Testing the right target and right drug at the right stage. Sci. Transl. Med. 3, 111cm33 (2011).","journal-title":"Sci. Transl. Med."},{"key":"BFnrneurol2015177_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/acprof:oso\/9780195328875.003.0020","volume-title":"Imaging the Aging Brain","author":"EM Reiman","year":"2009","unstructured":"Reiman, E. M. & Langbaum, J. B. Brain imaging in the evaluation of putative Alzheimer's disease slowing, risk-reducing and prevention therapies. In Imaging the Aging Brain (eds Jagust, W. J. & D'Esposito, M.) 319\u2013350 (Oxford University Press, 2009)."},{"key":"BFnrneurol2015177_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt59","volume":"3","author":"RJ Bateman","year":"2011","unstructured":"Bateman, R. J.  et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res. Ther. 3, 1 (2011).","journal-title":"Alzheimers Res. Ther."},{"key":"BFnrneurol2015177_CR5","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.2105\/AJPH.88.9.1337","volume":"88","author":"R Brookmeyer","year":"1998","unstructured":"Brookmeyer, R., Gray, S. & Kawas, C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am. J. Public Health 88, 1337\u20131342 (1998).","journal-title":"Am. J. Public Health"},{"key":"BFnrneurol2015177_CR6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2217\/bmm.09.91","volume":"4","author":"EM Reiman","year":"2010","unstructured":"Reiman, E. M., Langbaum, J. B. & Tariot, P. N. Alzheimer's Prevention Initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark. Med. 4, 3\u201314 (2010).","journal-title":"Biomark. Med."},{"key":"BFnrneurol2015177_CR7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert, M. S.  et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association workgroup. Alzheimers Dement. 7, 270\u2013279 (2011).","journal-title":"Alzheimers Dement."},{"key":"BFnrneurol2015177_CR8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling, R. A.  et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement. 7, 280\u2013292 (2011).","journal-title":"Alzheimers Dement."},{"key":"BFnrneurol2015177_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M.  et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. Alzheimers Dement. 7, 263\u2013269 (2011).","journal-title":"Alzheimers Dement."},{"key":"BFnrneurol2015177_CR10","volume-title":"Alzforum","author":"G Strobel","year":"2011","unstructured":"Strobel, G. Alzheimer's Prevention Initiative Workshop: scientists and regulators discuss preclinical AD trials. Alzforum \n                    [online]\n                    \n                  , (2011)."},{"key":"BFnrneurol2015177_CR11","volume-title":"Alzforum","author":"G Strobel","year":"2010","unstructured":"Strobel, G. Europe\u2013U. S. regulators mull prevention trials in familial AD. Alzforum \n                    [online]\n                    \n                  , (2010)."},{"key":"BFnrneurol2015177_CR12","volume-title":"Alzforum","author":"G Strobel","year":"2012","unstructured":"Strobel, G. DIAN grows, gets ready for therapeutic trials. Alzforum \n                    [online]\n                    \n                  , (2012)."},{"key":"BFnrneurol2015177_CR13","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1001\/jama.2008.683","volume":"300","author":"ST DeKosky","year":"2008","unstructured":"DeKosky, S. T.  et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 300, 2253\u20132262 (2008).","journal-title":"JAMA"},{"key":"BFnrneurol2015177_CR14","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S1474-4422(12)70206-5","volume":"11","author":"B Vellas","year":"2012","unstructured":"Vellas, B.  et al. Long-term use of standardised ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol. 11, 851\u2013859 (2012).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2015177_CR15","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1001\/jama.289.20.2651","volume":"289","author":"SA Shumaker","year":"2003","unstructured":"Shumaker, S. A.  et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289, 2651\u20132662 (2003).","journal-title":"JAMA"},{"key":"BFnrneurol2015177_CR16","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1001\/jama.291.24.2947","volume":"291","author":"SA Shumaker","year":"2004","unstructured":"Shumaker, S. A.  et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291, 2947\u20132958 (2004).","journal-title":"JAMA"},{"key":"BFnrneurol2015177_CR17","doi-asserted-by":"crossref","unstructured":"ADAPT Research Group  et al. Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch. Neurol. 65, 896\u2013905 (2008).","DOI":"10.1001\/archneur.2008.65.7.nct70006"},{"key":"BFnrneurol2015177_CR18","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1001\/jama.288.18.2271","volume":"288","author":"K Ball","year":"2002","unstructured":"Ball, K.  et al. Effects of cognitive training interventions with older adults: a randomized controlled trial. JAMA 288, 2271\u20132281 (2002).","journal-title":"JAMA"},{"key":"BFnrneurol2015177_CR19","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jalz.2010.01.013","volume":"6","author":"K Yurko-Mauro","year":"2010","unstructured":"Yurko-Mauro, K.  et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimers Dement. 6, 456\u2013464 (2010).","journal-title":"Alzheimers Dement."},{"key":"BFnrneurol2015177_CR20","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamainternmed.2013.13656","volume":"174","author":"JD Williamson","year":"2014","unstructured":"Williamson, J. D.  et al. Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Intern. Med. 174, 324\u2013333 (2014).","journal-title":"JAMA Intern. Med."},{"key":"BFnrneurol2015177_CR21","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","volume":"385","author":"T Ngandu","year":"2015","unstructured":"Ngandu, T.  et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 385, 2255\u20132263 (2015).","journal-title":"Lancet"},{"key":"BFnrneurol2015177_CR22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1602\/neurorx.1.2.189","volume":"1","author":"R Katz","year":"2004","unstructured":"Katz, R. Biomarkers and surrogate markers: an FDA perspective. NeuroRx 1, 189\u2013195 (2004).","journal-title":"NeuroRx"},{"key":"BFnrneurol2015177_CR23","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman, R. J.  et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795\u2013804 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2015177_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1001\/jamaneurol.2014.3314","volume":"72","author":"AS Fleisher","year":"2015","unstructured":"Fleisher, A. S.  et al. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol. 72, 316\u2013324 (2015).","journal-title":"JAMA Neurol."},{"issue":"1 Suppl.","key":"BFnrneurol2015177_CR25","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jalz.2011.09.172","volume":"8","author":"MW Weiner","year":"2012","unstructured":"Weiner, M. W.  et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 8 (1 Suppl.), S1\u2013S68 (2012).","journal-title":"Alzheimers Dement."},{"key":"BFnrneurol2015177_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.coph.2013.12.002","volume":"14","author":"AD Roses","year":"2014","unstructured":"Roses, A. D.  et al. New applications of disease genetics and pharmacogenetics to drug development. Curr. Opin. Pharmacol. 14, 81\u201389 (2014).","journal-title":"Curr. Opin. Pharmacol."},{"issue":"Suppl. 3","key":"BFnrneurol2015177_CR27","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3233\/JAD-2011-0059","volume":"26","author":"EM Reiman","year":"2011","unstructured":"Reiman, E. M.  et al. Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J. Alzheimers Dis. 26 (Suppl. 3), 321\u2013329 (2011).","journal-title":"J. Alzheimers Dis."},{"key":"BFnrneurol2015177_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/clpt.2012.222","volume":"93","author":"DG Crenshaw","year":"2013","unstructured":"Crenshaw, D. G.  et al. Using genetics to enable studies on the prevention of Alzheimer's disease. Clin. Pharmacol. Ther. 93, 177\u2013185 (2013).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BFnrneurol2015177_CR29","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.neurol.2013.07.017","volume":"169","author":"SM Mills","year":"2013","unstructured":"Mills, S. M.  et al. Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev. Neurol. (Paris) 169, 737\u2013743 (2013).","journal-title":"Rev. Neurol. (Paris)"},{"key":"BFnrneurol2015177_CR30","doi-asserted-by":"publisher","first-page":"975","DOI":"10.4155\/cli.12.93","volume":"2","author":"JC Morris","year":"2012","unstructured":"Morris, J. C.  et al. Developing an international network for Alzheimer research: the Dominantly Inherited Alzheimer Network. Clin. Investig. (Lond.) 2, 975\u2013984 (2012).","journal-title":"Clin. Investig. (Lond.)"},{"key":"BFnrneurol2015177_CR31","doi-asserted-by":"publisher","first-page":"228fs13","DOI":"10.1126\/scitranslmed.3007941","volume":"6","author":"RA Sperling","year":"2014","unstructured":"Sperling, R. A.  et al. The A4 study: stopping AD before symptoms begin? Sci. Transl. Med. 6, 228fs13 (2014).","journal-title":"Sci. Transl. Med."},{"key":"BFnrneurol2015177_CR32","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamaneurol.2014.803","volume":"71","author":"MC Donohue","year":"2014","unstructured":"Donohue, M. C.  et al. The Preclinical Alzheimer Cognitive Composite: measuring amyloid-related decline. JAMA Neurol. 71, 961\u2013970 (2014).","journal-title":"JAMA Neurol."},{"key":"BFnrneurol2015177_CR33","doi-asserted-by":"publisher","first-page":"652","DOI":"10.4088\/JCP.13m08927","volume":"75","author":"N Ayutyanont","year":"2014","unstructured":"Ayutyanont, N.  et al. The Alzheimer's Prevention Initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers. J. Clin. Psychiatry 75, 652\u2013660 (2014).","journal-title":"J. Clin. Psychiatry"},{"key":"BFnrneurol2015177_CR34","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.jalz.2014.02.002","volume":"10","author":"JB Langbaum","year":"2014","unstructured":"Langbaum, J. B.  et al. An empirically derived composite cognitive endpoint with improved power to track and evaluate treatments for preclinical Alzheimer's disease. Alzheimers Dement. 10, 666\u2013674 (2014).","journal-title":"Alzheimers Dement."},{"key":"BFnrneurol2015177_CR35","first-page":"74","volume":"1","author":"KT Saunders","year":"2014","unstructured":"Saunders, K. T.  et al. Arizona Alzheimer's Registry: strategy and outcomes of a statewide research recruitment registry. J. Prev. Alzheimers Dis. 1, 74\u201379 (2014).","journal-title":"J. Prev. Alzheimers Dis."},{"key":"BFnrneurol2015177_CR36","unstructured":"Guidance for industry. Alzheimer's disease: developing drugs for the treatment of early stage disease. Draft guidance. FDA \n                    [online]\n                    \n                  , (2013)."},{"key":"BFnrneurol2015177_CR37","unstructured":"Discussion paper on the clinical investigation of medicines for the treatment of Alzheimer's disease and other dementias. European Medicines Agency \n                    [online]\n                    \n                  , (2014)."},{"key":"BFnrneurol2015177_CR38","unstructured":"The A4 Study \n                    [online]\n                    \n                  , (2014)."},{"key":"BFnrneurol2015177_CR39","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    [online]\n                    \n                  , (2015)."},{"key":"BFnrneurol2015177_CR40","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody, R. S.  et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N. Engl. J. Med. 370, 311\u2013321 (2014).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol2015177_CR41","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    [online]\n                    \n                  , (2015)."},{"key":"BFnrneurol2015177_CR42","unstructured":"Alzheimer's Prevention Registry \n                    [online]\n                    \n                  , (2015)."},{"key":"BFnrneurol2015177_CR43","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    [online]\n                    \n                  , (2015)."},{"key":"BFnrneurol2015177_CR44","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/S1474-4422(12)70228-4","volume":"11","author":"EM Reiman","year":"2012","unstructured":"Reiman, E. M.  et al. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case\u2013control study. Lancet Neurol. 11, 1048\u20131056 (2012).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2015177_CR45","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/S1474-4422(12)70227-2","volume":"11","author":"AS Fleisher","year":"2012","unstructured":"Fleisher, A. S.  et al. Florbetapir PET analysis of amyloid-\u03b2 deposition in presenilin 1 E280A autosomal-dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol. 11, 1057\u20131065 (2012).","journal-title":"Lancet Neurol."},{"key":"BFnrneurol2015177_CR46","unstructured":"DIAN Observational Study \n                    [online]\n                    \n                  , (2013)."},{"key":"BFnrneurol2015177_CR47","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/alzrt213","volume":"5","author":"KL Moulder","year":"2013","unstructured":"Moulder, K. L.  et al. Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res. Ther. 5, 48 (2013).","journal-title":"Alzheimers Res. Ther."},{"key":"BFnrneurol2015177_CR48","unstructured":"DIAN-TU Pharma Consortium. Dominantly Inherited Alzheimer Network Trials Unit \n                    [online]\n                    \n                  , (2015)."},{"key":"BFnrneurol2015177_CR49","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    [online]\n                    \n                  , (2015)."},{"key":"BFnrneurol2015177_CR50","unstructured":"TOMMORROW study \n                    [online]\n                    \n                  , (2013)."},{"key":"BFnrneurol2015177_CR51","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    [online]\n                    \n                  , (2015)."},{"issue":"Suppl.","key":"BFnrneurol2015177_CR52","doi-asserted-by":"publisher","first-page":"P137","DOI":"10.1016\/j.jalz.2013.04.079","volume":"9","author":"K Welsh-Bohmer","year":"2013","unstructured":"Welsh-Bohmer, K.  et al. Challenges in international clinical trials to delay early symptomatic Alzheimer's disease. Alzheimers Dement. 9 (Suppl.), P137\u2013P138 (2013).","journal-title":"Alzheimers Dement."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2015.177.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2015.177","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2015.177.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:16:21Z","timestamp":1684469781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2015.177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,29]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["BFnrneurol2015177"],"URL":"https:\/\/doi.org\/10.1038\/nrneurol.2015.177","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,29]]},"assertion":[{"value":"29 September 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.M.R. receives research support from Genentech, Eli Lilly\/Avid Radiopharmaceuticals and Novartis. J.B.L. receives research support from Genentech and Novartis. P.N.T. has received research support from AC Immune, AstraZeneca, Avanir, Boehringer Ingelheim, Elan, Functional Neuromodulation, GE Healthcare, Genentech, Lilly, Lundbeck, Merck & Co., Novartis, Roche, Takeda and Targacept, and has personal financial interest in Abbott Laboratories, AbbVie, AC Immune, AstraZeneca, Auspex, Avanir, Boehringer Ingleheim, Chase Pharmaceuticals, Clintara, CME Group, Corium, GliaGure, Lilly, Lundbeck, Merck & Co., PlatformQ, Roche and Takeda. F.L. receives research support from Genentech. R.J.B. has received funding from Merck. He is a co-founder and part owner of C2N Diagnostics, and is a co-inventor on several patents under Washington University. He is on a scientific advisory board for FORUM pharmaceuticals, and has consulted for Eli Lilly, IMI, Merck, Novartis, Roche and Sanofi. J.C.M. is or was an investigator for clinical trials of antidementia drugs sponsored by the following companies: Janssen Immunotherapy, Pfizer, Eli Lilly\/Avid Radiopharmaceuticals, the SNIFF study, and the A4 trial. He has consulted for Lilly USA, ISIS Pharmaceuticals and the Charles Dana Foundation. He receives research support from Eli Lilly\/Avid Radiopharmaceuticals. R.A.S. has consulted for Biogen, Bracket, Genentech, Janssen and Roche. She receives research support from Eli Lilly and Co., Janssen Pharmaceuticals and Fidelity Biosciences. P.S.A. has consulted for the following companies: NeuroPhage, Eisai, Bristol-Myers Squibb, Eli Lilly, Merck, Roche, Amgen, Genentech, Novartis, Janssen, Biogen, iPerian, Anavex, Abbvie, Cohbar and Roivant. He has received research support from Eli Lilly and Janssen. A.D.R. is the CEO and only stock holder of Zinfandel Pharmaceuticals, which is allied with Takeda Pharmaceuticals. K.A.W.-B. receives research funding from Takeda through a contract with Duke University. S.W. is the Executive Director of the Fidelity Biosciences Research Initiative (FBRI), a subsidiary of Fidelity Investments. FBRI supports and facilitates the activities of the Collaboration for Alzheimer's Prevention and some of its affiliated studies. M.C.C. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}